$6100 | Single User
$10500 | Site License
$17000 | Enterprise License

Multiple Myeloma Forecast in 18 Major Markets 2016-2026
[Report Updated: 01-04-2016]

Published by Black Swan Analysis: 01 Apr 2016 | 81336 | In Stock
Related Topics: Multiple Myeloma , Myeloma

Introduction

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Multiple Myeloma in 18 Major Markets

Multiple Myeloma is a cancer of plasma cells and is characterized by the production of abnormal immunoglobulins (Ig) or antibodies, as well as an accumulation of malignant plasma cells in the bone marrow. In some cases it can be asymptomatic, known as “smouldering” Multiple Myeloma. Although there have been several advancements in understanding how the disease develops, it is unclear as to what exactly causes it.

This report provides the current incident population for Multiple Myeloma across 18 Major Markets (USA, France, Germany, Italy, Spain, United Kingdom, Ireland, Brazil, Japan, India, Saudi Arabia, South Africa, Canada, Mexico, Turkey, Argentina, Russia and Australia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Multiple Myeloma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Multiple Myeloma include:

• Anaemia

• Hypercalcaemia

• Increased % of bone marrow plasma cells (BMPC %)

• Thrombocytopenia

• Renal failure

• Elevated C-reactive protein

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Multiple Myeloma’s market to target the development of future products, pricing strategies and launch plans.

• Gain further insight into the incidence of the subdivided types of Multiple Myeloma and identify patient segments with high potential.

• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

• Provide a level of understanding on the impact from specific co-morbid conditions on Multiple Myeloma’s incident population.

• Identify sub-populations within Multiple Myeloma which require treatment.

• Gain an understanding of the specific markets that have the largest number of Multiple Myeloma patients.

Table of Contents
for Multiple Myeloma Forecast in 18 Major Markets 2016-2026 [Report Updated: 01-04-2016]

  • Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Multiple Myeloma in 18 Major Markets

    Multiple Myeloma is a cancer of plasma cells and is characterized by the production of abnormal immunoglobulins (Ig) or antibodies, as well as an accumulation of malignant plasma cells in the bone marrow. In some cases it can be asymptomatic, known as “smouldering” Multiple Myeloma. Although there have been several advancements in understanding how the disease develops, it is unclear as to what exactly causes it.

    This report provides the current incident population for Multiple Myeloma across 18 Major Markets (USA, France, Germany, Italy, Spain, United Kingdom, Ireland, Brazil, Japan, India, Saudi Arabia, South Africa, Canada, Mexico, Turkey, Argentina, Russia and Australia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

    Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Multiple Myeloma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

    Main symptoms and co-morbidities for Multiple Myeloma include:

    • Anaemia

    • Hypercalcaemia

    • Increased % of bone marrow plasma cells (BMPC %)

    • Thrombocytopenia

    • Renal failure

    • Elevated C-reactive protein

    This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

    Reason to buy

    • Able to quantify patient populations in global Multiple Myeloma’s market to target the development of future products, pricing strategies and launch plans.

    • Gain further insight into the incidence of the subdivided types of Multiple Myeloma and identify patient segments with high potential.

    • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

    • Provide a level of understanding on the impact from specific co-morbid conditions on Multiple Myeloma’s incident population.

    • Identify sub-populations within Multiple Myeloma which require treatment.

    • Gain an understanding of the specific markets that have the largest number of Multiple Myeloma patients.

List Of Tables
in Multiple Myeloma Forecast in 18 Major Markets 2016-2026 [Report Updated: 01-04-2016]

Table of Contents

• List of Tables and Figures

• Introduction

• Cause of the Disease

• Risk Factors & Prevention

• Diagnosis of the Disease

• Variation by Geography/Ethnicity

• Disease Prognosis & Clinical Course

• Key Co-morbid Conditions/ Features Associated with the Disease

• Methodology for Quantification of Patient Numbers

• Top-Line Incidence for Multiple Myeloma (MM)

• Staging of Multiple Myeloma Patients

• Features of Multiple Myeloma Patients

o Histopathology classification of MM patients

o Severity of Bone Lesions in MM patients

o Type of Immunoglobulin / Monoclonal Protein Type in MM patients

• Co-morbid Conditions Associated with Multiple Myeloma

• Abbreviations used in the Report

• Other Black Swan Analysis Publications

• Black Swan Analysis Online Patient-Based Databases

• Patient-Based Offering

• Online Pricing Data and Platforms

• References

• Appendix



List of Tables

• Durie-Salmon staging for MM

• International Staging System for MM

• Incidence of MM , total (000s)

• Incidence of MM, males (000s)

• Incidence of MM, females (000s)

• MM patients by stage – Durie-Salmon Staging system, total (000s)

• MM patients by stage – International Staging System, total (000s)

• Major Hystopathological types of MM patients, total (000s)

• Severity of bone lesions by type of MM patients, total (000s)

• Type of Ig / Monoclonal Proteins of MM patients, total (000s)

• Prevalence of Anaemia (<10g/dL) in MM patients, total (000s)

• Prevalence Renal Failure at diagnosis in MM patients, total (000s)

• Prevalence of BMPC ( ≥33 %) in MM patients, total (000s)

• Prevalence of Elevated C- reactive protein (≥ 0.8mg/dL) in MM patients, total (000s)

• Prevalence of Thrombocytopenia in MM patients, total (000s)

• Prevalence of Hypercalcaemia in MM patients, total (000s)

• Abbreviations and Acronyms used in the report

• USA Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• USA Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• France Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• France Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Germany Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Germany Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Italy Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Italy Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Spain Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Spain Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• UK Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• UK Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Ireland Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Ireland Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Japan Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Japan Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• India Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• India Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Saudi Arabia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Saudi Arabia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• South Africa Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• South Africa Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Canada Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Canada Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Mexico Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Mexico Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Turkey Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Turkey Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Australia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Australia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Argentina Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Argentina Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Russia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Russia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

• Brazil Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)

• Brazil Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)

List Of Figures, Charts and Diagrams
in Multiple Myeloma Forecast in 18 Major Markets 2016-2026 [Report Updated: 01-04-2016]

See List of Tables for the Figures

Additional Details

Publisher

Black Swan Analysis

Publisher Information

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we’ve seen what works and what doesn’t and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today’s complex healthcare marketplace.



The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.



We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.



The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.



Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Reference

81336 | MMYE0010416

Number of Pages

68

Report Format

PDF

Black Swan Analysis Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Black Swan Analysis

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we’ve seen what works and what doesn’t and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today’s complex healthcare marketplace.

The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.

We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.

The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.

Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Download Free Report Summary PDF

Multiple Myeloma Forecast in 18 Major Markets 2016-2026 [Report Updated: 01-04-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...